vitamins analogues  (Toronto Research Chemicals)

Journal: Nutrients

Article Title: Vitamin D Significantly Inhibits Carcinogenesis in the Mogp-TAg Mouse Model of Fallopian Tube Ovarian Cancer

doi: 10.3390/nu16193318

Figure Lengend Snippet: Effects of vitamin D on mogp-TAg mouse weight and calcium levels 8 and 12 weeks of age. ( A ) Trial design for the three different delivery systems for vitamin D in 5-week-old mice. Mice were euthanized at (1) 8 weeks of age (short term, 3 weeks of treatment) and (2) 12 weeks of age (long term, 7 weeks of treatment) for each delivery system. Sample size for each age group is n = 60 (a) Vehicle ( n = 10) and osmotic mini-pump (0.15 µg/kg/day of EB1089) ( n = 10), (b) Vehicle ( n = 10) and I.P. injection (0.5 µg/kg EB1089 twice per week) ( n = 10), and (c) Vehicle ( n = 10) and feed (25 IU cholecalciferol (Chole) per gram of diet ad libitum) ( n = 10). ( B ) Body weight gain (BWG) (grams) charts for the short- and long-term trials for each treatment group. ( C ) Calcium (Ca 2+ ) (mg/dL) levels in the plasma of vehicle ( n = 5) and vitamin D ( n = 5) treated mice in the 3 different treatment groups at 8 and 12 weeks of age. ( D ) Plasma quantification of 25(OH)D3 at 8 weeks for vehicle ( n = 6) and Chole ( n = 8) and at 12 weeks for vehicle ( n = 10) and Chole ( n = 8). ( E ) Western blot of p53, VDR, and PAX8 in the kidney of 8-week-old mice and the fallopian tubes of 5-, 8- and 12-week-old mice. Mean ± SEM. * ( p < 0.05), ** ( p < 0.005), t -test.

Article Snippet: Vitamin D delivery/formulation varied across the three groups: Trial 1—ALZET Osmotic Pump: Under isoflurane anesthesia, the mogp-TAg mice were subcutaneously implanted with an ALZET Osmotic Pump (model 1004, ALZET, Cupertino, CA, USA) through an incision between the scapulae for the delivery of vehicle (sterile polypropylene glycol and 0.05M Na 2 HPO 4 (80:20 v / v )) or a stock solution of 100 μg/mL EB1089 (activated vitamin D analogue) (Cat #3993 Tocris, Bristol, UK) diluted so that the pumps delivered 0.15 μg/kg/day of EB1089.

Techniques: Injection, Clinical Proteomics, Western Blot

Journal: Nutrients

Article Title: Vitamin D Significantly Inhibits Carcinogenesis in the Mogp-TAg Mouse Model of Fallopian Tube Ovarian Cancer

doi: 10.3390/nu16193318

Figure Lengend Snippet: Morphological changes in the fallopian tube at 8 and 12 weeks of age following treatments. ( A ) Representative H&E sections of the FT in the vehicle- and vitamin D-treated mice at 8 and 12 weeks of age following treatments in the 3 groups. Images were captured at 2× magnification. Scale bar: 1 mm. ( B ) Average cross-sectional area (pixel units) of the FT in Pump group at 8 weeks (vehicle ( n = 65) and EB1089 ( n = 47) and 12 weeks (vehicle ( n = 57) and EB1089 ( n = 45), Injection group at 8 weeks (vehicle ( n = 52) and EB1089 ( n = 65) and 12 weeks (vehicle ( n = 55) and EB1089 ( n = 39) and feed group at 8 weeks (vehicle ( n = 60) and Chole ( n = 61) and 12 weeks (vehicle ( n = 55) and Chole ( n = 54). mean ± SEM, * ( p < 0.05), ** ( p < 0.005), *** ( p < 0.0005), t -test.

Article Snippet: Vitamin D delivery/formulation varied across the three groups: Trial 1—ALZET Osmotic Pump: Under isoflurane anesthesia, the mogp-TAg mice were subcutaneously implanted with an ALZET Osmotic Pump (model 1004, ALZET, Cupertino, CA, USA) through an incision between the scapulae for the delivery of vehicle (sterile polypropylene glycol and 0.05M Na 2 HPO 4 (80:20 v / v )) or a stock solution of 100 μg/mL EB1089 (activated vitamin D analogue) (Cat #3993 Tocris, Bristol, UK) diluted so that the pumps delivered 0.15 μg/kg/day of EB1089.

Techniques: Injection